Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2019 · 10-Q
Revenue$2.16K$2.16Kno prior Q3 2018 on file Net Income-$547.45K-$547.45Kno prior Q3 2018 on file EPS Diluted$0.04$0.04no prior Q3 2018 on file Operating Income-$779,522— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-36089.0%
Net margin-25344.9%
ended May 31, 2019 · filed Jul 15, 2019 · 45 d after period end